دورية أكاديمية
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.
| العنوان: | A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study. |
|---|---|
| المؤلفون: | Ríos-Tamayo, Rafael, Soler, Juan Alfons, García-Sánchez, Ricarda, Pérez Persona, Ernesto, Arnao, Mario, García-Guiñón, Antoni, Domingo, Abel, González-Pardo, Miriam, de la Rubia, Javier, Mateos, María Victoria |
| المصدر: | Hematology; Dec2023, Vol. 28 Issue 1, p1-11, 11p |
| مصطلحات موضوعية: | MULTIPLE myeloma, MONOCLONAL antibodies, CLINICAL trials, PROGRESSION-free survival |
| مستخلص: | To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives. This was an observational, multicenter, ambispective study of RRMM treated with or without a mAb. A total of 171 patients were included. For the group treated without mAb, the median (95% CI) progression-free survival (PFS) to relapse was 22.4 (17.8-27.0) months; partial response or better (≥PR) and complete response or better (≥CR) was observed in 74.1% and 24.1% of patients, respectively; and median time to first response in first relapse was 2.0 months and in second relapse was 2.5 months. For the group of patients treated with mAb in first or second relapse, the median PFS was 20.9 (95% CI, could not be evaluated) months; the ≥ PR and ≥ CR rates were 76,2% and 28.6%, respectively; and the median time to first response in first relapse was 1.2 month and in second relapse was 1.0 months. The safety profiles for the combinations were consistent with those expected. The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials. [ABSTRACT FROM AUTHOR] |
| Copyright of Hematology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| قاعدة البيانات: | Complementary Index |
| ResultId |
1 |
|---|---|
| Header |
edb Complementary Index 174160183 1040 6 Academic Journal academicJournal 1040.24304199219 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=174160183&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Ríos-Tamayo%2C+Rafael%22">Ríos-Tamayo, Rafael</searchLink><br /><searchLink fieldCode="AR" term="%22Soler%2C+Juan+Alfons%22">Soler, Juan Alfons</searchLink><br /><searchLink fieldCode="AR" term="%22García-Sánchez%2C+Ricarda%22">García-Sánchez, Ricarda</searchLink><br /><searchLink fieldCode="AR" term="%22Pérez+Persona%2C+Ernesto%22">Pérez Persona, Ernesto</searchLink><br /><searchLink fieldCode="AR" term="%22Arnao%2C+Mario%22">Arnao, Mario</searchLink><br /><searchLink fieldCode="AR" term="%22García-Guiñón%2C+Antoni%22">García-Guiñón, Antoni</searchLink><br /><searchLink fieldCode="AR" term="%22Domingo%2C+Abel%22">Domingo, Abel</searchLink><br /><searchLink fieldCode="AR" term="%22González-Pardo%2C+Miriam%22">González-Pardo, Miriam</searchLink><br /><searchLink fieldCode="AR" term="%22de+la+Rubia%2C+Javier%22">de la Rubia, Javier</searchLink><br /><searchLink fieldCode="AR" term="%22Mateos%2C+María+Victoria%22">Mateos, María Victoria</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Hematology; Dec2023, Vol. 28 Issue 1, p1-11, 11p ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22MULTIPLE+myeloma%22">MULTIPLE myeloma</searchLink><br /><searchLink fieldCode="DE" term="%22MONOCLONAL+antibodies%22">MONOCLONAL antibodies</searchLink><br /><searchLink fieldCode="DE" term="%22CLINICAL+trials%22">CLINICAL trials</searchLink><br /><searchLink fieldCode="DE" term="%22PROGRESSION-free+survival%22">PROGRESSION-free survival</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives. This was an observational, multicenter, ambispective study of RRMM treated with or without a mAb. A total of 171 patients were included. For the group treated without mAb, the median (95% CI) progression-free survival (PFS) to relapse was 22.4 (17.8-27.0) months; partial response or better (≥PR) and complete response or better (≥CR) was observed in 74.1% and 24.1% of patients, respectively; and median time to first response in first relapse was 2.0 months and in second relapse was 2.5 months. For the group of patients treated with mAb in first or second relapse, the median PFS was 20.9 (95% CI, could not be evaluated) months; the ≥ PR and ≥ CR rates were 76,2% and 28.6%, respectively; and the median time to first response in first relapse was 1.2 month and in second relapse was 1.0 months. The safety profiles for the combinations were consistent with those expected. The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials. [ABSTRACT FROM AUTHOR] ) Array ( [Name] => Abstract [Label] => [Group] => Ab [Data] => <i>Copyright of Hematology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1080/16078454.2023.2178997
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 11
[StartPage] => 1
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => MULTIPLE myeloma
[Type] => general
)
[1] => Array
(
[SubjectFull] => MONOCLONAL antibodies
[Type] => general
)
[2] => Array
(
[SubjectFull] => CLINICAL trials
[Type] => general
)
[3] => Array
(
[SubjectFull] => PROGRESSION-free survival
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ríos-Tamayo, Rafael
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Soler, Juan Alfons
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => García-Sánchez, Ricarda
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pérez Persona, Ernesto
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Arnao, Mario
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => García-Guiñón, Antoni
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Domingo, Abel
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => González-Pardo, Miriam
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => de la Rubia, Javier
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mateos, María Victoria
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 12
[Text] => Dec2023
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 10245332
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 28
)
[1] => Array
(
[Type] => issue
[Value] => 1
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Hematology
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |